CN101932582B - 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 - Google Patents
詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 Download PDFInfo
- Publication number
- CN101932582B CN101932582B CN2008801029033A CN200880102903A CN101932582B CN 101932582 B CN101932582 B CN 101932582B CN 2008801029033 A CN2008801029033 A CN 2008801029033A CN 200880102903 A CN200880102903 A CN 200880102903A CN 101932582 B CN101932582 B CN 101932582B
- Authority
- CN
- China
- Prior art keywords
- disease
- purposes
- purposes according
- cancer
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
Abstract
本发明提供(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐形式,其有用于调节詹纳斯激酶活性,并有用于治疗与詹纳斯激酶活性相关的疾病,包括例如免疫相关疾病、皮肤病、骨髓增生性病症、癌症以及其他疾病。
Description
发明领域
本发明提供(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐形式,其有用于调节詹纳斯激酶(Janus kinase)活性,有用于治疗与詹纳斯激酶活性相关的疾病,所述疾病包括例如免疫相关疾病、皮肤病、骨髓增生性病症、癌症以及其它疾病。
发明背景
蛋白激酶(PK)是一组调节各种重要的生物学过程的酶,所述过程包括细胞生长、存活和分化;器官形成和形态发生;新血管形成;组织修复和再生等等。蛋白激酶通过催化蛋白质(或底物)的磷酸化并由此调节各种生物学环境(context)中的底物的细胞活性来发挥其生理功能。除了在正常组织/器官中的功能之外,许多蛋白激酶在包括癌症在内的许多人类疾病中还起着专门的作用。蛋白激酶的一个亚组(也被称为致癌蛋白激酶)在异常调节时可引起肿瘤形成和生长,并进一步有助于肿瘤的维持和发展(Blume-Jensen P等,Nature2001,411(6835):355-365)。迄今,致癌蛋白激酶代表用于癌症干涉和药物开发的最大的,最具有吸引力的蛋白质靶标组群之一。
詹纳斯激酶(JAK)家族在涉及免疫应答的细胞增殖和功能的细胞因子依赖性调节中发挥作用。当前,有四种已知的哺乳动物JAK家族成员:JAKl(也称为詹纳斯激酶-1)、JAK2(也称为詹纳斯激酶-2)、JAK3(也称为白细胞詹纳斯激酶;JAKL;L-JAK和詹纳斯激酶-3)和TYK2(也称为蛋白质-酪氨酸激酶2)。JAK蛋白的大小为120-140kDa,并包含7个保守的JAK同源(JH)结构域;其中的一个是功能性催化激酶结构域,另一个是潜在发挥调节功能和/或担当STATs的停靠位点(docking site)的假激酶结构域(Scott,Godshall等,2002,前述)。
在JAK激酶水平上阻断信号转导在人类癌症治疗上持有开发前景。抑制JAK激酶也预期对患有诸如牛皮癣和皮肤致敏之类的皮肤免疫病症的患者具有治疗益处。因此,人们广泛地寻找JAK激酶或相关激酶的抑制剂,几篇出版物报道了有效化合物种类,例如2006年12月12日申请的序列号为11/637,545的美国专利申请中报道了某些JAK抑制剂,其包括下文描述的(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈
因此,持续需要已知詹纳斯激酶抑制剂的新的或改进形式,以用于开发癌症和其它疾病治疗用的新的、改进的、以及更有效的药物制剂。本文描述的盐形式和方法针对这些需求以及其它目标。
发明概述
本发明尤其提供选自以下的盐:
(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈马来酸盐;
(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈硫酸盐;以及
(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈磷酸盐。
本发明进一步提供本发明的盐的制备方法,其包括将(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈与马来酸、硫酸或磷酸化合(combining)。
本发明进一步提供组合物,其包含本发明的盐形式以及至少一种药学上可接受的载体。
本发明进一步提供调节JAK活性的方法,其包括使JAK与本发明的盐接触。
本发明进一步提供在患者中治疗疾病的方法,其中所述疾病与JAK活性相关,所述方法包括对所述患者施用治疗有效量的本发明的盐。
本发明进一步提供在患者中治疗癌症、皮肤病或炎症的方法,所述方法包括对所述患者施用治疗有效量的本发明的盐。
本发明进一步提供本发明的盐,其在通过疗法(therapy)治疗人或动物体的方法中使用。
本发明进一步提供本发明的盐,其用于治疗癌症、皮肤病或炎症。
本发明进一步提供本发明的盐在制备药物中的用途,所述药物用于治疗本文所记载的疾病或病症中的任意种。
详述
本发明尤其提供JAK抑制剂(R)-3-(4-(7H-吡咯并[2,3-d ]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐,所述盐选自马来酸盐、硫酸盐和磷酸盐。这些盐调节一种或多种JAK的活性,且有用于例如治疗与JAK的表达或活性相关的疾病。
相比于游离碱形式和其它的盐形式,本发明的盐具有众多优点。尤其,这些盐是高度结晶的,其易于制备药物制剂,并改进活性成分的一般处理、操作和储存。相比于游离碱形式,本发明的盐还具有优异的水溶性、解离率、化学稳定性(具有较长的货架期)、与赋形剂的相容性、以及再现性。
在一些实施方案中,本发明的盐是基本分离的。“基本分离的”指该盐至少部分地或基本上从其在其中形成或被检测的环境中分离。部分分离可以包括例如富集(enriched in)本发明的盐的组合物。基本分离可以包括含有至少约50重量%、至少约60重量%、至少约70重量%、至少约80重量%、至少约90重量%、至少约95重量%、至少约97重量%或至少约99重量%的所述盐的组合物。
本发明的盐也包括存在于所述盐中的原子的所有同位素。同位素包括原子序数相同但质量数不同的那些原子。例如,氢的同位素包括氚和氘。
可以使用已知技术来制备本发明的盐。常规地,通过以下方式来制备盐形式:在溶液中,使游离碱化合物与含有所需盐形式的阴离子的酸化合,然后从反应溶液中分离(例如通过结晶、沉淀、蒸发等)盐产物固体。也可以使用其它的盐形成技术。
使用方法
本发明的盐可以调节一种或多种詹纳斯激酶(JAKs)的活性。术语“调节”意指提高或降低JAK激酶家族的一种或多种成员的活性的能力。因此,通过使JAK与本文描述的化合物或组合物中的一种或多种接触,而在调节JAK的方法中使用本发明化合物。在一些实施方案中,本发明的盐可以担当一种或多种的JAK的抑制剂。在一些实施方案中,本发明化合物可以起刺激一种或多种的JAK的活性的作用。在其它实施方案中,可以在需要受体调节的个体中通过施用调节量的本发明的盐,将本发明化合物用于调节JAK的活性。
本发明的盐结合和/或调节的JAK包括JAK家族的任何成员。在一些实施方案中,所述JAK为JAK1、JAK2、JAK3或TYK2。在一些实施方案中,所述JAK为JAK1或JAK2。在一些实施方案中,所述JAK是JAK2。在一些实施方案中,所述JAK为JAK3。
本发明的盐可以是选择性的。“选择性的”指与至少一种其它的JAK相比,本发明化合物分别以更大的亲和性或效能结合或抑制JAK。在一些实施方案中,本发明化合物是相对于JAK3和/或TYK2的JAK1或JAK2的选择性抑制剂。在一些实施方案中,本发明的盐是JAK2(例如,相对于JAK1、JAK3和TYK2)的选择性抑制剂。不希望受到理论束缚,由于JAK3的抑制剂可以导致免疫抑制效应,因此,相对于JAK3,对JAK2具有选择性,有用于治疗癌症(例如多发性骨髓瘤)的化合物可提供具有更少免疫抑制副作用的额外优势。选择性可以为至少约5倍、10倍,至少约20倍,至少约50倍,至少约100倍,至少约200倍,至少约500倍或至少约1000倍。可以通过本领域的常规方法来测定选择性。在一些实施方案中,可以根据每一种酶的Km来测试选择性。在一些实施方案中,可以通过细胞ATP浓度来确定本发明的盐相对于JAK3的对JAK2的选择性。
本发明的另一方面涉及在个体(例如患者)中通过对需要这种治疗的个体施用治疗有效量或剂量的本发明的盐或其药物组合物,来治疗JAK相关的疾病或病症的方法。JAK相关的疾病可以包括与JAK的表达或活性(包括超表达和/或异常的活性水平)直接或间接相关的任何疾病、障碍或病症。JAK相关的疾病也可以包括可以通过调节JAK活性来预防、改善或治愈的任何疾病、障碍或病症。
JAK相关的疾病的例子包括涉及免疫系统的疾病,其包括例如器官移植排斥(例如,同种异体移植物排斥和移植物抗宿主病)。
JAK相关的疾病的其它例子包括自身免疫性疾病,例如多发性硬化、类风湿性关节炎、幼年性关节炎、I型糖尿病、狼疮、牛皮癣、炎性肠病、溃疡性结肠炎、克罗恩病、重症肌无力、免疫球蛋白肾病、自身免疫性甲状腺病等。在一些实施方案中,自身免疫性疾病为自身免疫性大疱性皮肤病,例如寻常性天疱疮(PV)或大疱性类天疱疮(BP)。
JAK相关的疾病的其它例子包括过敏性病症,例如哮喘、食物过敏、特应性皮炎和鼻炎。JAK相关的疾病的其它例子包括病毒性疾病,例如,埃巴病毒(EBV)、乙型肝炎、丙型肝炎、HIV、HTLV 1、水痘-带状疱疹病毒(VZV)和人乳头状瘤病毒(HPV)。
JAK相关的疾病或病症的其它例子包括皮肤病,例如牛皮癣(例如,寻常性牛皮癣)、特应性皮炎、皮疹、皮肤刺激、皮肤致敏(sensitization)(例如,接触性皮炎或过敏性接触性皮炎)。例如,包括一些药品在内的某些物质在局部施用时可以引起皮肤致敏。在一些实施方案中,将至少一种本发明的JAK抑制剂连同引起有害的致敏的药剂一起施用或按序施用可以有助于治疗此类有害的致敏或皮炎。在一些实施方案中,通过局部施用至少一种本发明的JAK抑制剂来治疗皮肤病。
在其它实施方案中,JAK相关的疾病为癌症,包括表征为实体瘤的那些癌症(例如,前列腺癌、肾癌、肝癌、胰腺癌、胃癌、乳腺癌、肺癌、头和颈部的癌症、甲状腺癌、胶质母细胞瘤、卡波西肉瘤、卡斯尔曼病(Castleman′sdisease)、黑色素瘤等)、血液癌(hematological cancers)(例如淋巴瘤;白血病,例如急性成淋巴细胞白血病、急性髓细胞源性白血病(AML)、或多发性骨髓瘤)、以及皮肤癌(例如皮肤T细胞淋巴瘤(CTCL)和皮肤B细胞淋巴瘤)。皮肤T细胞淋巴瘤的例子包括塞泽里综合征(Sezary syndrome)和蕈样肉芽肿病。
JAK相关的疾病可以进一步包括表征为突变型JAK2的表达的那些疾病,例如在假激酶结构域(例如,JAK2V617F)中具有至少一处突变的那些疾病。
JAK相关的疾病可以进一步包括骨髓增生性病症(MPD),例如真性红细胞增多(PV)、自发性凝血细胞增多(ET)、伴有骨髓纤维化的骨髓外化生(MMM)、慢性髓细胞源性白血病(CML)、慢性髓单核细胞白血病(CMML)、嗜酸性细胞增多综合征(HES)、系统性肥大细胞病(SMCD)等。
其它的JAK相关的疾病包括炎症和炎性疾病。炎性疾病的例子包括眼部的炎性疾病(例如虹膜炎、葡萄膜炎、巩膜炎、结膜炎,或相关疾病)、呼吸道的炎性疾病(例如,包括鼻和鼻窦的上呼吸道炎症,例如鼻炎或鼻窦炎;或者包括支气管炎、慢性阻塞性肺病的下呼吸道炎症等)、诸如心肌炎的炎性肌病、以及其它的炎性疾病。可通过本发明化合物治疗的其它炎性疾病包括系统性炎症反应综合征(SIRS)和脓毒性休克。
本文所描述的JAK抑制剂可以进一步用于治疗缺血性再灌注损伤或与诸如休克或心跳停搏之类的炎性缺血性事件相关的疾病或病症。本文所描述的JAK抑制剂可以进一步用于治疗厌食症、恶病质或疲劳,例如由癌症引起或与癌症相关的那些。本文所描述的JAK抑制剂可以进一步用于治疗再狭窄、硬皮病或纤维化。本文所描述的JAK抑制剂可以进一步用于治疗与缺氧或星形细胞增生相关的病症,例如糖尿病性视网膜病、癌症或神经变性。参见例如,Dudley,A.C.等,Biochem.J.2005,390(部分2):427-36和Sriram,K.等,J.Biol.Chem.2004,279(19):19936-47。Epub 2004年3月2日。
本文所描述的JAK抑制剂可以进一步用于治疗痛风和由于例如良性前列腺肥大或良性前列腺增生而引起的前列腺尺寸增大。
本文使用的术语“接触”指将所指出的各部分(moieties)在体外系统或体内系统中聚集在一起(bringing together)。例如,使JAK与本发明的盐“接触”包括对具有JAK的个体或患者(例如人)施用本发明的盐,以及例如,将本发明的盐引入含有含JAK的细胞制剂或纯化制剂的样本中。
本文使用的术语“个体”或“患者”可以互相换用,指任何动物,包括哺乳动物,优选小鼠、大鼠、其它啮齿类、兔、狗、猫、猪、牛、羊、马或灵长类,最优选人。
本文使用的短语“治疗有效量”指引起研究者、兽医、内科医生或其它临床医生在组织、系统、动物、个体或人中所寻求的引起生物学或医学反应的活性盐或药物试剂的量。
本文使用的术语“治疗”指以下中的一种或多种:(1)预防疾病;例如在可能易患某种疾病、病症或障碍,但还没有经历或表现该疾病的病理或症状的个体中预防所述疾病、病症或障碍;(2)抑制疾病;例如,在经历或表现某种疾病、病症或障碍的病理或症状的个体中抑制所述疾病、病症或障碍;以及(3)改善疾病;例如,在经历或表现某种疾病、病症或障碍的病理或症状的个体中改善所述疾病、病症或障碍(即,逆转(reversing)病理和/或症状),例如降低疾病的严重性。
联合治疗
一种或多种其它药物试剂,例如化疗剂、抗炎剂、类固醇、免疫抑制剂、以及Bcr-Abl、Flt-3、RAF和FAK激酶抑制剂(例如WO 2006/056399中所描述的那些抑制剂),或者其它药剂可以与本发明的盐联合使用,以治疗JAK相关的疾病、障碍或病症。可以同时或按序对患者施用所述一种或多种其它药物试剂。
化疗剂的例子包括蛋白酶体(proteosome)抑制剂(例如硼替佐米)、沙利度胺、来那度胺(revlimid)、以及DNA损害剂(例如美法仑、多柔比星、环磷酰胺、长春新碱、依托泊甙、卡莫司汀等等。
类固醇的例子包括皮质类固醇,例如地塞米松或泼尼松。
Bcr-Abl抑制剂的例子包括美国专利No.5,521,184、WO 04/005281、EP2005/009967、EP2005/010408以及序列号为60/578,491的美国申请中所公开的属(genera)和种(species)的化合物及其药学上可接受的盐。
合适的Flt-3抑制剂的例子包括WO 03/037347、WO 03/099771和WO04/046120中所公开的化合物及其药学上可接受的盐。
合适的RAF抑制剂的例子包括WO 00/09495和WO 05/028444中所公开的化合物及其药学上可接受的盐。
合适的FAK抑制剂的例子包括WO 04/080980、WO 04/056786、WO03/024967、WO 01/064655、WO 00/053595和WO 01/014402中所公开的化合物及其药学上可接受的盐。
在一些实施方案中,本发明的盐形式可以与其他的激酶抑制剂(例如伊马替尼)联合使用,特别用于治疗对伊马替尼或其他激酶有抗性的患者。
在一些实施方案中,一种或多种本发明盐形式可以与化疗剂联合使用,用于治疗癌症(例如多发性骨髓瘤),且与单独使用化疗剂的反应相比,可以改进治疗反应,而不加剧其毒性影响。用于治疗多发性骨髓瘤的其它药物试剂的例子例如可以非限制性地包括美法仑、美法仑+泼尼松(MP)、多柔比星、地塞米松和万珂(硼替佐米)。用于治疗多发性骨髓瘤的其它药物试剂包括Bcr-Abl、Flt-3、RAF和FAK激酶抑制剂。将本发明的JAK抑制剂与其他的药剂联合的理想结果是增效或协同的效应。另外,用本发明的JAK抑制剂治疗可以逆转多发性骨髓瘤细胞对例如地塞米松之类的药剂的抗性。所述药剂可与本发明化合物以单剂型或连续剂型(single or continuous dosage form)联合,或者所述药剂作为单独的剂型可以同时或按序施用。
在一些实施方案中,将诸如地塞米松之类的皮质类固醇与至少一种JAK抑制剂联合施用于患者,其中间歇施用,而非连续施用地塞米松。
在一些其它实施方案中,在骨髓移植或干细胞移植之前、期间和/或之后,将一种或多种本发明的JAK抑制剂与其他的治疗剂联合施用于患者。
药物制剂和剂型
当用作药物时,可以药物组合物的形式施用本发明的盐。这些组合物可以用制药领域众所周知的方式来制备,并可以通过各种途径施用,施用途径取决于希望局部治疗还是全身治疗,以及待治疗的区域。可以局部施用(包括透皮、表皮、眼部以及粘膜施用(包括鼻内、阴道和直肠递送);肺部施用(例如通过吸入或吹入粉末或气溶胶,包括通过喷雾器;气管内或鼻内施用);口服或胃肠外施用。胃肠外施用包括静脉内、动脉内、皮下、腹膜内、肌内施用,或注射或输注;或者颅内施用,例如鞘内施用,或者心室内施用。胃肠外施用可以采取单一大丸剂的形式,或者可以例如通过连续灌注泵施用。局部施用的药物组合物和制剂可以包括透皮贴剂、软膏剂、洗剂、乳膏剂、凝胶、滴剂、栓剂、喷雾剂、液体剂和散剂。常规的药物载体、水性、粉末或油性基质、增稠剂等等可能是必需的或希望的。经涂覆的(coated)避孕套、手套等等也可能是有用的。
本发明还包括药物组合物,其含有上述作为活性成分的一种或多种本发明化合物与一种或多种药学上可接受的载体(赋形剂)的组合。在制备本发明组合物中,活性成分通常与赋形剂混合,被赋形剂稀释或包封在载体中,所述载体为例如胶囊、小药囊、纸或其他容器之类的形式。当赋形剂担当稀释剂时,其可以是固体、半固体或液体材料,作为活性成分的赋形剂、载体或介质。因此,所述组合物可以为以下形式:片剂、丸剂、散剂、锭剂、小药囊、扁囊剂、酏剂、混悬剂、乳剂、溶液剂、糖浆剂、气雾剂(作为固体,或在液体介质中)、含有例如至多10重量%活性化合物的软膏剂、软胶囊或硬胶囊、栓剂、无菌注射溶液以及无菌包装粉末(sterile packaged powders)。
在制备制剂时,可以研磨活性化合物,以在与其它成分混合之前提供适当的粒度。如果活性化合物基本上是不可溶的,则可以将其研磨至小于200目的粒度。如果活性化合物基本上是水溶性的,则可以通过研磨调整粒度,以提供在制剂中的基本均匀分布,例如约40目。
可以使用已知的研磨程序(例如湿法研磨)研磨本发明化合物,以获得适合于片剂制剂或其他制剂类型的粒度。可以通过本领域已知的方法(例如参见国际专利申请No.WO 2002/000196)来制备本发明化合物的细粒状(纳米微粒)制剂。
合适的赋形剂的一些例子包括乳糖、右旋糖、蔗糖、山梨醇、甘露醇、淀粉、阿拉伯树胶、磷酸钙、海藻酸盐、黄芪胶、明胶、硅酸钙、微晶纤维素、聚乙烯吡咯烷酮、纤维素、水、糖浆和甲基纤维素。所述制剂可以另外包括:润滑剂,例如滑石、硬脂酸镁以及矿物油;湿润剂;乳化及悬浮剂;防腐剂,例如苯甲酸甲酯和苯甲酸丙基羟基酯;甜味剂;以及矫味剂。通过使用本领域已知的程序对本发明组合物进行配制,以便在对患者施用后提供快速释放、持续释放或延迟释放活性成分。
可以将所述组合物配制为单位剂型(unit dosage form),每一剂量含有约5到约1000mg(1g)(更通常为约100到约500mg)的活性成分。术语“单位剂型”是指适合作为人类对象或其他动物用的单剂量(unitary dosages)的物理离散单位(physically discrete units),每一单位含有经计算产生所需治疗效果的预定量活性物质,以及合适的药物赋形剂。
活性化合物可以在宽泛的剂量范围内是有效的,通常以药物有效量进行施用。但应理解,通常由医生根据有关情况来确定化合物的实际施用量,所述情况包括待治疗的病症、所选择的给药途径、实际施用的化合物、个体患者的年龄、体重及反应、患者症状的严重性等。
对于制备诸如片剂等固体组合物,将主要的活性成分与药物赋形剂混合以形成含有本发明化合物的均匀混合物的固体预配制(preformulation)组合物。当提及这些预配制组合物为均匀的时,活性成分通常均匀地分散遍布于组合物中,从而该组合物易于细分成同等有效的单位剂型,例如片剂、丸剂和胶囊。然后将该固体预配制物细分成以上所述类型的单位剂型,所述单位剂型含有例如约0.1至约1000mg本发明的活性成分。
可以对本发明的片剂或丸剂进行包衣或其他形式的复合,以提供具有延长作用的优点的剂型。例如,片剂或丸剂可以包含内剂量组分和外剂量组分,后者是前者的包膜(envelope)形式。可以通过肠溶层(enteric layer)将该两种组分分开,所述肠溶层用于在胃中抵抗崩解,使内组分完整进入十二指肠或被延迟释放。可以使用各种材料用于此类肠溶层或包衣,此类材料包括许多高分子酸,以及高分子酸与诸如虫胶、鲸蜡醇和醋酸纤维素等的混合物。
用于口服或注射给药的其中可掺混本发明的化合物和组合物的液体形式包括水溶液、适当矫味的糖浆、水性混悬液或油性混悬液、用食用油(例如棉籽油、芝麻油、椰油或花生油)矫味的乳液、以及酏剂和类似的药物载体。
用于吸入或吹入的组合物包括药学上可接受的水溶剂或有机溶剂或其混合物中的溶液和混悬液,以及粉末。液体或固体组合物可以含有上文所描述的合适的药学上可接受的赋形剂。在一些实施方案中,经口或经鼻呼吸道途径施用所述组合物,以获得局部或全身效果。可通过使用惰性气体对组合物进行雾化。可以从雾化装置直接吸入雾化溶液,或者可将雾化装置与面罩(face maskstent)或间歇正压呼吸机(intermittent positive pressure breathing machine)连接。可通过以适当方式递送所述制剂的装置经口或经鼻施用溶液、混悬液或粉末组合物。
施用于患者的盐或组合物的量将根据所施用的物质、施用目的(例如预防或治疗)、患者的状况、给药方式等而变化。在治疗性应用中,可以对已经罹患某一疾病的患者施用足以治愈或至少部分消除该疾病及其并发症的症状的量的组合物。有效剂量取决于所治疗的疾病状况以及主治医生根据以下因素的判断:例如疾病严重性、患者的年龄、体重和一般状况等。
对患者施用的组合物可以是以上所述的药物组合物形式。可以通过常规灭菌技术对这些组合物进行灭菌,或者将这些组合物无菌过滤。可以将水溶液包装,以直接使用,或者将其冻干,在施用前,将冻干制剂与无菌水性载体混合。化合物制剂的pH通常在3-11之间,更优选为5-9,最优选为7-8。应理解,使用某种前述的赋形剂、载体或稳定剂将导致形成药用盐。
本发明的盐的治疗剂量可以根据例如以下因素而变化:进行治疗的具体用途、化合物的给药方式,患者的健康或状况、以及开处方医生的判断。本发明的盐在药物组合物中的比例或浓度可以根据许多因素而变化,所述因素包括剂量、化学特征(例如疏水性)和给药途径。例如本发明的盐可以提供于生理缓冲剂水溶液中,用于胃肠外施用,所述生理缓冲剂水溶液含有约0.1至10%w/v的本发明化合物。一些典型的剂量范围为约1μg/kg体重/天至约1g/kg体重/天。在一些实施方案中,剂量范围为约0.01mg/kg体重/天至约100mg/kg体重/天。剂量可能取决于以下变量:例如疾病或病症的类型和进展程度、具体患者的总体健康状况、所选择的化合物的相对生物学功效、赋形剂的配方,以及其给药途径。可以由得自体外或动物模型测试系统的剂量-反应曲线推断有效剂量。
本发明的组合物可以进一步包括一种或多种另外的药物试剂,例如化疗剂、类固醇、抗炎化合物或免疫抑制剂,上文中列举了它们的例子。
标记的化合物和分析方法
本发明的另一方面涉及标记的本发明盐(放射性标记、荧光标记等),其不仅在成像技术中有用,还在分析中有用,既在体外以及体内用于对包括人的组织样本中的JAK进行定位或定量,以及用于通过抑制标记化合物的结合来鉴定JAK配体。因此,本发明包括含有此类标记化合物的JAK分析。
本发明进一步包括同位素标记的本发明的盐。“同位素标记的”或“放射性标记的”化合物是其中一个或多个原子被原子质量或质量数不同于通常在自然中发现的(即天然存在)的原子质量或质量数的原子替换或取代的本发明的盐。可以并入本发明化合物的合适的放射性核素包括但不限于2H(也写作D,代表氘)、3H(也写作T,代表氚)、11C、13C、14C、13N、15N、15O、17O、18O、18F、35S、36Cl、82Br、75Br、76Br、77Br、123I、124I、125I和131I。并入本发明放射性标记的化合物的放射性核素将取决于该放射性标记的化合物的具体应用。例如,对于体外金属蛋白酶标记和竞争分析,掺有3H、14C、82Br、125I、131I、35S或的化合物通常最有用。对于放射性成像应用,11C、18F、125I、123I、124I、131I、75Br、76Br或77Br通常最有用。
应当理解,“放射性标记的”或“标记的化合物”是并有至少一种放射性核素的盐。在一些实施方案中,放射性核素选自3H、14C、125I、35S和82Br。
本发明可以进一步包括将放射性同位素并入本发明化合物的合成方法。将放射性同位素并入有机化合物的合成方法在本领域是众所周知的,本领域普通技术人员将容易地认识到可应用于本发明化合物的方法。
本发明的标记盐可以用于筛选分析,以鉴定/评价化合物。例如,将标记的新近合成或鉴定的化合物(即,测试化合物)与JAK接触,通过跟踪标记,监测其浓度变化,可以评价其结合JAK的能力。例如,可以评价测试化合物(被标记)降低另一种已知与JAK结合的化合物(即标准化合物)的结合的能力。因此,测试化合物与标准化合物竞争结合JAK的能力与其结合亲和性直接相关。相反地,在一些其他的筛选分析中,将标准化合物标记而不将测试化合物标记。因此,为了评价标准化合物和测试化合物之间的竞争,对标记的标准化合物的浓度进行监测,从而确定测试化合物的相对结合亲和性。
试剂盒
本发明还包括药物试剂盒,其有用于例如治疗或预防JAK相关的疾病或病症,例如癌症、炎症或皮肤病,所述药物试剂盒包括一个或多个容纳包含治疗有效量的本发明的盐的药物组合物的容器。如果需要的话,此类试剂盒可以进一步包括一种或多种不同的常规药物试剂盒组分,例如含有一种或多种药学上可接受的载体的容器,其它的容器等,这些对于本领域技术人员将是显而易见的。在试剂盒中还可以包括说明书(插页或标签形式),说明待施用的各组分的量、给药指南、和/或混合组分的指南。
通过具体实施例对本发明进行更为详细的描述。以下给出的实施例仅用于描述的目的,并无意在以任何方式限制本发明。本领域技术人员将容易地认识到各种非关键的参数,可以改变或修改这些参数以产生基本相同的结果。
实施例
实施例1:(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈马来酸盐的制备
向试管中加入(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈(153.7mg,0.5mmol)和马来酸(61.7mg),然后加入异丙醇(IPA)(4mL)。将所得混合物加热至清澈,冷却至室温,之后搅拌另外2.5小时。通过过滤收集沉淀物,用0.8mL的冷IPA洗涤滤饼。真空干燥滤饼至恒重,得到最终的盐产物(173mg)。
该马来酸盐经H1NMR显示为1∶1的盐,通过X射线粉末衍射(XRPD)证实结晶度。差示扫描量热法(DSC)显示在约175.96℃(开始于175.67℃)处有一个尖锐的熔融峰。产物通过热重分析(TGA)显示在高达150℃下仅有轻微的重量损失。
实施例2:(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈磷酸盐的制备
在试管中加入(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈(153.5mg)和磷酸(56.6mg),然后加入异丙醇(IPA)(5.75mL)。将所得混合物加热至清澈,冷却至室温,之后搅拌另外2小时。通过过滤收集沉淀物,用0.6mL的冷IPA洗涤滤饼。真空干燥滤饼至恒重,得到最终的盐产物(171.7mg)。
该磷酸盐经H1NMR显示为1∶1的盐,通过X射线粉末衍射(XRPD)证实结晶度。差示扫描量热法(DSC)显示在约198.66℃处有一个尖锐的熔融峰。产物通过TGA显示在高达200℃下几乎没有(little)重量损失。
实施例3:(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈硫酸盐的制备
在测试管中加入(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈(153.0mg)和硫酸(56.1mg),之后加入乙腈(7.0mL)。将所得混合物加热至清澈,冷却至室温,之后搅拌另外2小时。通过过滤收集沉淀物,用0.8mL的冷乙腈洗涤滤饼。真空干燥滤饼至恒重,得到最终的盐产物(180mg)。
该硫酸盐经H1NMR显示为1∶1的盐,通过X射线粉末衍射(XRPD)证实结晶度。差示扫描量热法(DSC)显示在约186.78℃处有一个尖锐的熔融峰。产物通过TGA显示在高达175℃下几乎没有重量损失。
实施例A
体外JAK激酶分析
可以按照以下描述于Park等,Analytical Biochemistry(分析生物化学)1999,269,94-104中的体外分析来测试试验化合物对JAK靶标的抑制活性。使用杆状病毒在昆虫细胞中表达具有N末端的组氨酸标签的人JAK1(a.a.837-1142)、Jak2(a.a.828-1132和Jak3(a.a.781-1124)的催化结构域,并进行纯化。通过测量生物素化肽的磷酸化来分析JAK1、JAK2或JAK3的催化活性。通过均相时间分辨荧光(HTRF)检测磷酸化的肽。测定化合物对反应液中的每一种激酶的IC50,所述反应液在50mM Tris(pH 7.8)缓冲液中含有酶、ATP和500nM肽,所述缓冲液含有100mM NaCl、5mM DTT和0.1mg/mL(0.01%)的BSA。反应液中的ATP浓度对于Jak1为90μM,对于Jak2为30μM,对于Jak3为3μM。在室温下进行反应1小时,之后用分析缓冲液(PerkinElmer,波士顿,MA)中的20μL 45mM EDTA、300nM SA-APC、6nM Eu-Py20终止反应。与铕标记的抗体结合40分钟,在Fusion读板仪(Perkin Elmer,波士顿,MA)上测定HTRF信号。发现本发明的磷酸盐和相应的游离碱化合物针对JAK1、JAK2和JAK3中的每一种的IC50值都小于50nM。
除本文所描述的那些内容,从前述说明书对本发明作出的各种修改对本领域技术人员而言是显而易见的。此类修改也有意落入所附权利要求书的保护范围内。本申请所引用的每一参考文献通过引用全文并入本文中。
Claims (61)
1.盐,其选自:
(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈马来酸盐;
(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈硫酸盐;和
(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈磷酸盐。
2.根据权利要求1所述的盐,其为(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈马来酸盐。
3.根据权利要求1所述的盐,其为(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈硫酸盐。
4.根据权利要求1所述的盐,其为(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈磷酸盐。
5.权利要求1-4中任一项所述的盐的制备方法,其包括使(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈与马来酸、硫酸或磷酸化合。
6.组合物,其包含至少一种权利要求1-4中任一项所述的盐以及至少一种药学上可接受的载体。
7.根据权利要求6所述的组合物,其适合于口服或局部施用。
8.根据权利要求6所述的组合物,其适合于局部施用。
9.权利要求1-4中任一项所述的盐在制备调节JAK活性的药物中的用途。
10.根据权利要求9所述的用途,其中所述调节为抑制。
11.权利要求1-4中任一项所述的盐在制备用于在患者中治疗疾病的药物中的用途,其中所述疾病与JAK活性相关。
12.根据权利要求11所述的用途,其中所述疾病为同种异体移植物排斥或移植物抗宿主病。
13.根据权利要求11所述的用途,其中所述疾病为自身免疫性疾病。
14.根据权利要求13所述的用途,其中所述自身免疫性疾病为皮肤病、多发性硬化、类风湿性关节炎、幼年性关节炎、I型糖尿病、狼疮、炎性肠病、克罗恩病、重症肌无力、免疫球蛋白肾病、心肌炎或自身免疫性甲状腺病。
15.根据权利要求13所述的用途,其中所述自身免疫性疾病为大疱性皮肤病。
16.根据权利要求15所述的用途,其中所述大疱性皮肤病为寻常性天疱疮或大疱性类天疱疮。
17.根据权利要求11所述的用途,其中所述疾病为皮肤病。
18.根据权利要求17所述的用途,其中所述皮肤病为特应性皮炎、牛皮癣、皮肤致敏、皮肤刺激、皮疹、接触性皮炎或过敏性接触性致敏。
19.根据权利要求11所述的用途,其中所述疾病为病毒性疾病。
20.根据权利要求19所述的用途,其中所述病毒性疾病为埃巴病毒、乙型肝炎、丙型肝炎、HIV、HTLV1、水痘-带状疱疹病毒或人乳头状瘤病毒。
21.根据权利要求11所述的用途,其中所述疾病为癌症。
22.根据权利要求21所述的用途,其中所述癌症为实体瘤。
23.根据权利要求21所述的用途,其中所述癌症为前列腺癌、肾癌、肝癌、乳腺癌、肺癌、甲状腺癌、卡波西肉瘤、卡斯尔曼病或胰腺癌。
24.根据权利要求23所述的用途,其中所述癌症为前列腺癌。
25.根据权利要求21所述的用途,其中所述癌症为血液癌。
26.根据权利要求25所述的用途,其中所述癌症为淋巴瘤、白血病或多发性骨髓瘤。
27.根据权利要求21所述的用途,其中所述癌症为皮肤癌。
28.根据权利要求27所述的用途,其中所述皮肤癌为皮肤T细胞淋巴瘤或皮肤B细胞淋巴瘤。
29.根据权利要求21所述的用途,其中所述癌症为多发性骨髓瘤。
30.根据权利要求11所述的用途,其中所述疾病表征为突变型JAK2。
31.根据权利要求30所述的用途,其中所述突变型JAK2的至少一种突变位于所述JAK2的假激酶结构域中。
32.根据权利要求11所述的用途,其中所述疾病为骨髓增生性病症。
33.根据权利要求32所述的用途,其中所述骨髓增生性病症为真性红细胞增多、自发性凝血细胞增多、伴有骨髓纤维化的骨髓外化生、慢性髓细胞源性白血病、慢性髓单核细胞白血病、嗜酸性细胞增多综合征或系统性肥大细胞病。
34.根据权利要求11所述的用途,其中所述疾病为炎性疾病。
35.根据权利要求34所述的用途,其中所述疾病为眼部炎性疾病。
36.根据权利要求35所述的用途,其中所述疾病为虹膜炎、葡萄膜炎、巩膜炎或结膜炎。
37.根据权利要求34所述的用途,其中所述疾病为呼吸道的炎性疾病。
38.根据权利要求34所述的用途,其中所述炎性疾病涉及上呼吸道。
39.根据权利要求34所述的用途,其中所述炎性疾病涉及下呼吸道。
40.根据权利要求34所述的用途,其中所述炎性疾病为炎性肌病。
41.根据权利要求34所述的用途,其中所述炎性疾病为心肌炎。
42.根据权利要求11所述的用途,其中所述疾病为缺血性再灌注或与缺血性事件相关的疾病。
43.根据权利要求11所述的用途,其中所述疾病为由癌症引起的或与癌症相关的厌食症或恶病质。
44.根据权利要求11所述的用途,其中所述疾病为由癌症引起的或与癌症相关的疲劳。
45.权利要求1-4中任一项所述的盐在制备用于在患者中治疗癌症的药物中的用途。
46.权利要求1-4中任一项所述的盐在制备用于在患者中治疗皮肤病的药物中的用途。
47.权利要求1-4中任一项所述的盐在制备用于在患者中治疗炎症的药物中的用途。
48.权利要求1-4中任一项所述的盐在制备用于在患者中治疗类风湿性关节炎的药物中的用途。
49.权利要求1-4中任一项所述的盐在制备用于在患者中治疗前列腺癌的药物中的用途。
50.权利要求1-4中任一项所述的盐在制备用于在患者中治疗牛皮癣的药物中的用途。
51.权利要求1-4中任一项所述的盐在制备用于在患者中治疗多发性骨髓瘤的药物中的用途。
52.权利要求1-4中任一项所述的盐在制备用于在患者中治疗伴有骨髓纤维化的骨髓外化生的药物中的用途。
53.权利要求1-4中任一项所述的盐在制备用于在患者中治疗真性红细胞增多的药物中的用途。
54.权利要求1-4中任一项所述的盐在制备用于在患者中治疗自发性凝血细胞增多的药物中的用途。
55.权利要求1-4中任一项所述的盐在制备用于在患者中治疗蕈样肉芽肿病的药物中的用途。
56.权利要求1-4中任一项所述的盐在制备用于在患者中治疗血液癌的药物中的用途。
57.权利要求1-4中任一项所述的盐在制备用于在患者中治疗慢性髓细胞源性白血病的药物中的用途。
58.权利要求1-4中任一项所述的盐在制备用于在患者中治疗急性成淋巴细胞白血病的药物中的用途。
59.权利要求1-4中任一项所述的盐在制备用于在患者中治疗慢性髓单核细胞白血病的药物中的用途。
60.(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈磷酸盐在制备用于在患者中治疗骨髓增生性病症的药物中的用途。
61.权利要求60所述的用途,其中所述骨髓增生性病症为伴有骨髓纤维化的骨髓外化生、真性红细胞增多或自发性凝血细胞增多。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310367212.9A CN103524509B (zh) | 2007-06-13 | 2008-06-12 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94370507P | 2007-06-13 | 2007-06-13 | |
US60/943705 | 2007-06-13 | ||
PCT/US2008/066662 WO2008157208A2 (en) | 2007-06-13 | 2008-06-12 | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310367212.9A Division CN103524509B (zh) | 2007-06-13 | 2008-06-12 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101932582A CN101932582A (zh) | 2010-12-29 |
CN101932582B true CN101932582B (zh) | 2013-09-25 |
Family
ID=40029273
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801029033A Active CN101932582B (zh) | 2007-06-13 | 2008-06-12 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
CN201310367212.9A Active CN103524509B (zh) | 2007-06-13 | 2008-06-12 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310367212.9A Active CN103524509B (zh) | 2007-06-13 | 2008-06-12 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
Country Status (42)
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060106020A1 (en) * | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
NZ592990A (en) | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
EP2348023B9 (en) | 2005-12-13 | 2017-03-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
JP5492565B2 (ja) * | 2006-12-22 | 2014-05-14 | インサイト・コーポレイション | Janusキナーゼ阻害剤としての置換複素環 |
CN101932582B (zh) | 2007-06-13 | 2013-09-25 | 因塞特公司 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
EP2220068B1 (en) * | 2007-11-16 | 2016-01-27 | Incyte Holdings Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
UA101493C2 (ru) * | 2008-03-11 | 2013-04-10 | Инсайт Корпорейшн | Производные азетидина и циклобутана как ингибиторы jak |
JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
KR20110124787A (ko) | 2009-02-27 | 2011-11-17 | 암비트 바이오사이언시즈 코포레이션 | Jak 키나아제 조절 퀴나졸린 유도체 및 이의 사용 방법 |
SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
CN102458581B (zh) | 2009-05-22 | 2016-03-30 | 因塞特控股公司 | 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物 |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
KR20180126619A (ko) * | 2009-10-09 | 2018-11-27 | 인사이트 홀딩스 코포레이션 | 3-(4-(7H-피롤로〔2,3-d〕피리미딘-4-일)-1H-피라졸-1-일)-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체 |
SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
BR112012020693B1 (pt) * | 2010-02-18 | 2020-05-12 | Incyte Holdings Corporation | Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende |
ME02386B (me) | 2010-03-10 | 2016-09-20 | Incyte Holdings Corp | Derivati piperidin-4-il azetidina kao inhibitori jak1 |
KR102303885B1 (ko) | 2010-05-21 | 2021-09-24 | 인사이트 홀딩스 코포레이션 | Jak 저해제에 대한 국소 제형 |
US8633207B2 (en) | 2010-09-01 | 2014-01-21 | Ambit Biosciences Corporation | Quinazoline compounds and methods of use thereof |
KR101913293B1 (ko) * | 2010-11-02 | 2018-10-30 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 탈모 질환의 치료 방법 |
AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
EP2640723A1 (en) * | 2010-11-19 | 2013-09-25 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
CA2827673C (en) * | 2011-02-18 | 2020-10-27 | Novartis Pharma Ag | Mtor/jak inhibitor combination therapy |
PE20140604A1 (es) * | 2011-06-14 | 2014-05-13 | Novartis Ag | Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa |
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
CN102921007B (zh) * | 2011-08-09 | 2014-12-10 | 中国科学院上海生命科学研究院 | 防治胰岛素抵抗和糖尿病的方法和试剂 |
CA2844507A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | Jak pi3k/mtor combination therapy |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CN104185420B (zh) | 2011-11-30 | 2017-06-09 | 埃默里大学 | 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂 |
US10821111B2 (en) | 2011-11-30 | 2020-11-03 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
WO2013173506A2 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
CA2879603A1 (en) | 2012-07-27 | 2014-01-30 | Ratiopharm Gmbh | Oral dosage forms for modified release comprising ruxolitinib |
PE20151141A1 (es) | 2012-11-01 | 2015-08-06 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de jak |
EA201590930A1 (ru) | 2012-11-15 | 2015-08-31 | Инсайт Корпорейшн | Лекарственные формы руксолитиниба с замедленным высвобождением |
JP6397831B2 (ja) | 2013-03-06 | 2018-09-26 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤の製造方法及びその中間体 |
US20140343034A1 (en) * | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
ME02763B (me) | 2013-05-17 | 2018-01-20 | Incyte Corp | Derivati bipirazola kao inhibitori jak |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
EP3049110A2 (en) * | 2013-09-23 | 2016-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for targeting tumor microenvironment and for preventing metastasis |
KR20230044320A (ko) | 2014-04-08 | 2023-04-03 | 인사이트 코포레이션 | Jak 및 pi3k 억제제 조합에 의한 b-세포 악성종양의 치료 |
SG10201809518QA (en) | 2014-04-30 | 2018-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
CN105218548A (zh) * | 2014-06-09 | 2016-01-06 | 上海海和药物研究开发有限公司 | 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途 |
AR101504A1 (es) | 2014-08-11 | 2016-12-21 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 |
HRP20220738T1 (hr) | 2014-08-11 | 2022-08-19 | Acerta Pharma B.V. | Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1 |
EP3179991B1 (en) | 2014-08-11 | 2021-10-06 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
WO2016026974A1 (en) * | 2014-08-21 | 2016-02-25 | Ratiopharm Gmbh | Oxalate salt of ruxolitinib |
EP3183253B1 (en) * | 2014-08-21 | 2018-06-27 | ratiopharm GmbH | Salt of (r)-3-(4-(7h-pyrrolo [2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid |
WO2016035014A1 (en) * | 2014-09-01 | 2016-03-10 | Sun Pharmaceutical Industries Limited | Processes for the preparation of ruxolitinib phosphate |
WO2016063294A2 (en) * | 2014-10-20 | 2016-04-28 | Msn Laboratories Private Limited | Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof |
CZ2014773A3 (cs) | 2014-11-10 | 2016-05-18 | Zentiva, K.S. | Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu |
WO2016077595A1 (en) | 2014-11-12 | 2016-05-19 | The General Hospital Corporation | Methods for treating neurodegenerative diseases |
CZ2015496A3 (cs) | 2015-07-14 | 2017-01-25 | Zentiva, K.S. | Krystalické formy solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a jejich příprava |
DK3402515T3 (da) | 2016-01-12 | 2021-11-15 | Oncotracker Inc | Forbedrede fremgangsmåder til monitorering af et individs immunstatus |
CZ201629A3 (cs) | 2016-01-22 | 2017-08-02 | Zentiva, K.S. | Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy |
CN107573348B (zh) * | 2016-01-29 | 2019-09-03 | 上海宣创生物科技有限公司 | 巴瑞克替尼三氟乙酸盐b晶型及其制备方法 |
CN107573349A (zh) * | 2016-02-01 | 2018-01-12 | 上海宣创生物科技有限公司 | 巴瑞克替尼磷酸盐h晶型及其制备方法 |
WO2017173451A1 (en) * | 2016-04-01 | 2017-10-05 | The General Hospital Corporation | Targeting innate immune signaling in neuroinflammation and neurodegeneration |
CN107759600A (zh) * | 2016-06-16 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
RU2644155C1 (ru) * | 2016-12-12 | 2018-02-08 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | 2-(3-(4-(7H-пирроло[2,3-d]пиримидин-4-ил)-1H-пиразол-1-ил)-1-(этилсульфонил)азетидин-3-ил)ацетонитрила геминафтилдисульфонат в качестве ингибитора Янус киназ |
WO2018231944A1 (en) | 2017-06-13 | 2018-12-20 | Berenson James R | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
US10800775B2 (en) | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
CA3081751A1 (en) | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
CR20200379A (es) | 2018-01-30 | 2021-03-05 | Incyte Corp | Procesos e intermedio para elaborar un inhibidor de jak campo técnico |
KR20200128043A (ko) | 2018-02-16 | 2020-11-11 | 인사이트 코포레이션 | 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제 |
CA3092931A1 (en) | 2018-03-08 | 2019-09-12 | Novartis Ag | Use of an anti-p-selectin antibody |
CA3095487A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
MA52655A (fr) | 2018-03-30 | 2021-02-17 | Incyte Corp | Biomarqueurs pour maladie cutanée inflammatoire |
WO2019200030A1 (en) | 2018-04-13 | 2019-10-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
KR102545594B1 (ko) | 2018-07-31 | 2023-06-21 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
SG11202100525SA (en) | 2018-08-10 | 2021-02-25 | Aclaris Therapeutics Inc | Pyrrolopyrimidine itk inhibitors |
WO2020039401A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | Treatment comprising il-1βeta binding antibodies and combinations thereof |
KR20210056380A (ko) | 2018-09-04 | 2021-05-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 5원 내지 7원 헤테로사이클릭 아마이드 |
MX2021004946A (es) | 2018-10-31 | 2021-07-15 | Incyte Corp | Terapia combinada para tratamiento de enfermedades hematológicas. |
CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3,5-二甲氧基苯基)氨基)喹喔啉衍生物 |
EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
SG11202109563WA (en) | 2019-03-05 | 2021-09-29 | Incyte Corp | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
EP3947737A2 (en) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
EP3955920A1 (en) | 2019-04-16 | 2022-02-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
KR20220004726A (ko) | 2019-05-02 | 2022-01-11 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | Jak 억제제로서의 치환된 피롤로피리딘 |
CA3150975A1 (en) | 2019-06-10 | 2020-12-17 | Incyte Corporation | Topical treatment of vitiligo by a jak inhibitor |
JP2022538836A (ja) | 2019-06-27 | 2022-09-06 | クリスパー セラピューティクス アクチェンゲゼルシャフト | がんを治療するためのキメラ抗原受容体t細胞及びnk細胞阻害剤の使用 |
CA3153076A1 (en) | 2019-09-05 | 2021-03-11 | Incyte Corporation | Ruxolitinib formulation for reduction of itch in atopic dermatitis |
CN114423786A (zh) | 2019-09-16 | 2022-04-29 | 诺华股份有限公司 | 高亲和力的、配体阻断性、人源化的抗T细胞免疫球蛋白结构域和粘蛋白结构域3(TIM-3)IgG4抗体用于治疗骨髓纤维化的用途 |
WO2021053489A1 (en) | 2019-09-16 | 2021-03-25 | Novartis Ag | Use of an mdm2 inhibitor for the treatment of myelofibrosis |
JP2023506118A (ja) | 2019-10-16 | 2023-02-15 | インサイト・コーポレイション | 皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用 |
US11738026B2 (en) | 2019-11-22 | 2023-08-29 | Incyte Corporation | Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor |
WO2021206766A1 (en) | 2020-04-09 | 2021-10-14 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
US11324750B2 (en) | 2020-04-09 | 2022-05-10 | Children's Hospital Medical Center | Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection |
EP3892280A3 (en) | 2020-04-09 | 2022-01-12 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
EP4157831A1 (en) | 2020-06-02 | 2023-04-05 | Incyte Corporation | Processes of preparing a jak1 inhibitor |
CN115835868A (zh) | 2020-06-03 | 2023-03-21 | 因赛特公司 | 用于治疗骨髓增生性赘生物的鲁索利替尼与incb057643的组合 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
US20220023344A1 (en) | 2020-06-26 | 2022-01-27 | Crispr Therapeutics Ag | Allogeneic cell therapy of acute lymphoblastic leukemia using genetically engineered t cells targeting cd19 |
PE20231308A1 (es) | 2020-08-18 | 2023-08-24 | Incyte Corp | Proceso e intermedios para preparar un inhibidor de jak1 |
KR20230096973A (ko) | 2020-08-18 | 2023-06-30 | 인사이트 코포레이션 | Jak 저해제를 제조하기 위한 방법 및 중간체 |
EP4213800A1 (en) | 2020-09-16 | 2023-07-26 | Incyte Corporation | Topical treatment of vitiligo |
CA3197645A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Topical ruxolitinib for treating lichen planus |
EP4225317A1 (en) | 2020-10-08 | 2023-08-16 | Novartis AG | Use of an erk inhibitor for the treatment of myelofibrosis |
WO2022074599A1 (en) | 2020-10-08 | 2022-04-14 | Novartis Ag | Use of an erk inhibitor for the treatment of myelofibrosis |
TW202237125A (zh) | 2020-12-04 | 2022-10-01 | 美商英塞特公司 | 用於治療皮膚疾病之jak抑制劑與維生素d類似物 |
CA3204374A1 (en) | 2020-12-08 | 2022-06-16 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
KR20230157307A (ko) | 2021-01-11 | 2023-11-16 | 인사이트 코포레이션 | Jak 경로 억제제 및 rock 억제제를 포함하는 병용 요법 |
EP4297750A1 (en) | 2021-02-25 | 2024-01-03 | Impact Biomedicines, Inc. | Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis |
WO2023102559A1 (en) | 2021-12-03 | 2023-06-08 | Incyte Corporation | Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
WO2023245053A1 (en) | 2022-06-14 | 2023-12-21 | Incyte Corporation | Solid forms of a jak inhibitor and process of preparing the same |
WO2024028193A1 (en) | 2022-08-03 | 2024-02-08 | Medichem, S.A. | Stable oral pharmaceutical formulation containing ruxolitinib hemifumarate |
Family Cites Families (286)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2985589A (en) | 1957-05-22 | 1961-05-23 | Universal Oil Prod Co | Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets |
US3832460A (en) * | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
US4140755A (en) | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
GB2030584B (en) | 1978-10-03 | 1983-03-23 | Lankro Chem Ltd | Photopolymerisable solder resist compositions |
JPS5553537A (en) | 1978-10-13 | 1980-04-19 | Barron Robert Michael | Abrasive foam material and its preparation |
DE3036390A1 (de) | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen |
DE3220113A1 (de) | 1982-05-28 | 1983-12-01 | Basf Ag, 6700 Ludwigshafen | Difluormethoxiphenylthiophosphorsaeureester |
US4402832A (en) | 1982-08-12 | 1983-09-06 | Uop Inc. | High efficiency continuous separation process |
US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
US4498991A (en) | 1984-06-18 | 1985-02-12 | Uop Inc. | Serial flow continuous separation process |
NL8403224A (nl) | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
CA1306260C (en) | 1985-10-18 | 1992-08-11 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
JPH0781138B2 (ja) | 1986-12-02 | 1995-08-30 | 株式会社資生堂 | 抗酸化剤 |
EP0495982B1 (en) | 1989-10-11 | 1996-06-12 | Teijin Limited | Bicyclic pyrimidine derivative, method of producing the same, and pharmaceutical preparation containing the same as active ingredient |
IT1258781B (it) | 1992-01-16 | 1996-02-29 | Zambon Spa | Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
US6638905B2 (en) | 1993-06-18 | 2003-10-28 | The Salk Institute For Biological Studies | Cloning and recombinant production of CFR receptor(s) |
JPH0710876A (ja) | 1993-06-24 | 1995-01-13 | Teijin Ltd | 4位に環状アミノ基を有するピロロ[2,3―d]ピリミジン |
EP0727217A3 (en) | 1995-02-10 | 1997-01-15 | Suntory Ltd | Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient |
US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
KR19990028709A (ko) | 1995-07-05 | 1999-04-15 | 미리암 디. 메코너헤이 | 살진균 피리미디논 |
CZ1598A3 (cs) | 1995-07-06 | 1998-04-15 | Novartis Ag | Pyrrolopyrimidiny a způsoby jejich přípravy |
US5630943A (en) | 1995-11-30 | 1997-05-20 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Discontinuous countercurrent chromatographic process and apparatus |
GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
EP0906099A4 (en) | 1996-04-03 | 2001-02-07 | Merck & Co Inc | CANCER TREATMENT METHOD |
WO1997038664A2 (en) | 1996-04-18 | 1997-10-23 | Merck & Co., Inc. | A method of treating cancer |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
EP0934270A1 (en) | 1996-05-30 | 1999-08-11 | Merck & Co., Inc. | A method of treating cancer |
US6624138B1 (en) * | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
EP0973396A4 (en) | 1997-04-07 | 2001-02-07 | Merck & Co Inc | METHOD FOR TREATING CANCER |
US6060038A (en) | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
US6063284A (en) | 1997-05-15 | 2000-05-16 | Em Industries, Inc. | Single column closed-loop recycling with periodic intra-profile injection |
EP1001782A4 (en) | 1997-08-11 | 2002-01-30 | Boehringer Ingelheim Pharma | 5,6-HETEROARYL-DIPYRIDO (2-3-b: 3 ', 2'-f) AZEPINS AND THE USE THEREOF FOR PROPHYLAXIS AND TREATMENT OF HIV INFECTIONS |
US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
IL139811A0 (en) | 1998-06-04 | 2002-02-10 | Abbott Lab | Cell adhesion-inhibiting antinflammatory compounds |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
HUP0102574A3 (en) | 1998-06-19 | 2002-01-28 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds |
CN1152031C (zh) | 1998-08-11 | 2004-06-02 | 诺瓦提斯公司 | 具有血管生成抑制活性的异喹啉衍生物 |
JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h―イミダゾピリジン誘導体 |
TR200100708T2 (tr) * | 1998-09-10 | 2001-07-23 | Nycomed Danmark A/S | İlaç maddelerine mahsus çabuk salımlı farmasötik bileşimler. |
JP3869128B2 (ja) | 1998-09-11 | 2007-01-17 | 株式会社ルネサステクノロジ | 半導体集積回路装置の製造方法 |
US6375839B1 (en) | 1998-10-29 | 2002-04-23 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic zones |
US6413419B1 (en) | 1998-10-29 | 2002-07-02 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic |
FR2785196B1 (fr) | 1998-10-29 | 2000-12-15 | Inst Francais Du Petrole | Procede et dispositif de separation avec des zones chromatographiques a longueur variable |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
WO2000051614A1 (en) | 1999-03-03 | 2000-09-08 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferases |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
WO2000063168A1 (en) | 1999-04-16 | 2000-10-26 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
WO2001027104A1 (fr) | 1999-10-13 | 2001-04-19 | Banyu Pharmaceutical Co., Ltd. | Derives d'imidazolidinone a substitution |
NZ518884A (en) * | 1999-12-10 | 2004-02-27 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds |
IL150388A0 (en) * | 1999-12-24 | 2002-12-01 | Aventis Pharma Ltd | Azaindoles |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
DE60100866T2 (de) | 2000-04-07 | 2004-07-29 | Laboratoire Medidom S.A. | Cyklosporin, Hyaluronsäure und Polysorbate enthaltenes Augenarzneimittel |
WO2001081345A1 (fr) | 2000-04-20 | 2001-11-01 | Mitsubishi Pharma Corporation | Composes d'amides aromatiques |
ATE502941T1 (de) | 2000-04-25 | 2011-04-15 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta |
US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
JP4954426B2 (ja) | 2000-06-16 | 2012-06-13 | キュリス,インコーポレイテッド | 血管形成調節組成物及び利用 |
US6335342B1 (en) * | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
CN100548375C (zh) * | 2000-06-23 | 2009-10-14 | 田边三菱制药株式会社 | 抗肿瘤作用增效剂 |
ATE423120T1 (de) | 2000-06-26 | 2009-03-15 | Pfizer Prod Inc | Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe |
CA2413330A1 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
JP4377583B2 (ja) | 2000-12-05 | 2009-12-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | C−junn末端キナーゼ(jnk)および他のタンパク質キナーゼのインヒビター |
GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
EP1351936A1 (en) | 2001-01-15 | 2003-10-15 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
CA2436487A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd. | Methods of inhibiting kinases |
CA2446864C (en) | 2001-05-16 | 2011-02-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of src and other protein kinases |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
CA2455181C (en) * | 2001-08-01 | 2010-04-06 | Merck & Co., Inc. | Benzimidazo[4,5-f]isoquinolinone derivatives |
AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
US6429231B1 (en) | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
CA2462657C (en) | 2001-10-30 | 2011-04-26 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
CA2468942A1 (en) | 2001-11-30 | 2003-06-12 | Teijin Limited | Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound |
GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
US7304061B2 (en) * | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
ATE381332T1 (de) | 2002-05-02 | 2008-01-15 | Merck & Co Inc | Tyrosinkinase-hemmer |
BR0309844A (pt) | 2002-05-07 | 2005-02-15 | Control Delivery Sys Inc | Processos para formação de um dispositivo para a distribuição de droga |
GB2392154B (en) | 2002-05-23 | 2005-01-19 | Cytopia Pty Ltd | Protein Kinase Inhibitors |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
CA2490340A1 (en) | 2002-06-26 | 2004-01-08 | Idemitsu Kosan Co., Ltd. | Hydrogenated copolymer, production process for the same and hot melt adhesive composition using the same |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
EP1541563A4 (en) | 2002-07-10 | 2007-11-07 | Ono Pharmaceutical Co | ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE |
CN1684738A (zh) | 2002-09-20 | 2005-10-19 | 爱尔康公司 | 细胞因子合成抑制剂用于治疗干眼病的用途 |
US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
WO2004041814A1 (en) | 2002-11-04 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Heteroaryl-pyramidine derivatives as jak inhibitors |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
EP1572213A1 (en) | 2002-11-26 | 2005-09-14 | Pfizer Products Inc. | Method of treatment of transplant rejection |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
UY28126A1 (es) | 2002-12-24 | 2004-06-30 | Alcon Inc | Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular |
TW200418806A (en) | 2003-01-13 | 2004-10-01 | Fujisawa Pharmaceutical Co | HDAC inhibitor |
US7444183B2 (en) * | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
US7407962B2 (en) | 2003-02-07 | 2008-08-05 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors or protein kinases |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
JP2006522124A (ja) | 2003-04-03 | 2006-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用な組成物 |
SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
FR2857454B1 (fr) | 2003-07-08 | 2006-08-11 | Aventis Pasteur | Dosage des acides techoiques des bacteries gram+ |
US20050043346A1 (en) | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
AU2004268621C1 (en) | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
WO2005026129A1 (en) | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
ATE490771T1 (de) | 2003-10-24 | 2010-12-15 | Santen Pharmaceutical Co Ltd | Therapeutisches mittel für keratokonjunktive erkrankungen |
MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
EP1689407A1 (en) | 2003-11-25 | 2006-08-16 | Pfizer Products Inc. | Method of treatment of atherosclerosis |
RU2006120956A (ru) | 2003-12-17 | 2008-01-27 | Пфайзер Продактс Инк. (Us) | Пирроло{2, 3-d}пиримидиновые соединения для лечения отторжения трансплантата |
JP5138938B2 (ja) | 2003-12-19 | 2013-02-06 | プレキシコン インコーポレーテッド | Ret調節剤の開発のための化合物および方法 |
TW200528450A (en) | 2003-12-19 | 2005-09-01 | Schering Corp | Thiadiazoles as cxc-and cc-chemokine receptor ligands |
NZ547696A (en) | 2003-12-23 | 2009-12-24 | Astex Therapeutics Ltd | Pyrazole derivatives as protein kinase modulators |
US20050153989A1 (en) | 2004-01-13 | 2005-07-14 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
EP1744751A4 (en) | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | TREATMENT OF SYNUCLEINOPATHIES |
PL2332940T3 (pl) | 2004-03-30 | 2013-03-29 | Vertex Pharma | Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych |
AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
WO2005105988A2 (en) | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Crystal structure of human jak3 kinase domain complex and binding pockets thereof |
US20060106020A1 (en) * | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
CA2563569A1 (en) | 2004-05-03 | 2005-11-10 | Novartis Ag | Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor |
CA2566158A1 (en) | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
MXPA06014247A (es) | 2004-06-10 | 2007-03-12 | Irm Llc | Compuestos y composiciones como inhibidores de la proteina quinasa. |
US8039674B2 (en) | 2004-06-23 | 2011-10-18 | Ono Pharmaceutical Co., Ltd. | Compound having S1P receptor binding potency and use thereof |
EP2325184A1 (en) | 2004-06-30 | 2011-05-25 | Vertex Pharmceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
US7138423B2 (en) * | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
FR2873691B1 (fr) | 2004-07-29 | 2006-10-06 | Sanofi Synthelabo | Derives d'amino-piperidine, leur preparation et leur application en therapeutique |
WO2006013114A1 (en) | 2004-08-06 | 2006-02-09 | Develogen Aktiengesellschaft | Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
CN101006186A (zh) | 2004-08-23 | 2007-07-25 | 财团法人牧岩生命工学研究所 | 用于检测sars冠状病毒的引物和探针,包括该引物和/或探针的试剂盒及其检测方法 |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
DK1802625T3 (da) | 2004-10-13 | 2008-09-01 | Hoffmann La Roche | Disubstituerede pyrazolobenzodiazepiner der er nyttige som inhibitorer af CDK2 og angiogenese og til behandling af bryst-, tyktarms-, lunge- og prostatacancer |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
US7528138B2 (en) | 2004-11-04 | 2009-05-05 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
CN101106983A (zh) | 2004-11-24 | 2008-01-16 | 诺瓦提斯公司 | JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合 |
US7517870B2 (en) | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
WO2006065916A1 (en) | 2004-12-14 | 2006-06-22 | Alcon, Inc. | Method of treating dry eye disorders using 13(s)-hode and its analogs |
US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
AR053992A1 (es) | 2004-12-22 | 2007-05-30 | Astrazeneca Ab | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. |
JP2008528477A (ja) | 2005-01-20 | 2008-07-31 | ファイザー・リミテッド | 化合物 |
RU2434871C2 (ru) * | 2005-02-03 | 2011-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Пирролопиримидины, применимые в качестве ингибиторов протеинкиназы |
US7683171B2 (en) | 2005-02-04 | 2010-03-23 | Bristol-Myers Squibb Company | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
RU2383545C2 (ru) | 2005-03-15 | 2010-03-10 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
RU2007140903A (ru) | 2005-04-05 | 2009-05-20 | Фармакопия, Инк. (Us) | Производные пурина и имидазопиридина для иммуносупрессии |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
RU2435769C2 (ru) * | 2005-05-20 | 2011-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирролопиридины, полезные в качестве ингибиторов протеинкиназы |
JP2008543775A (ja) | 2005-06-08 | 2008-12-04 | ターゲジェン インコーポレーティッド | 眼の障害を治療するための方法および組成物 |
AU2006254840B2 (en) | 2005-06-08 | 2012-08-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
ES2371397T3 (es) | 2005-06-22 | 2011-12-30 | Plexxikon, Inc. | Derivados de pirrolo[2,3-b]piridina como inhibidores de proteínas cinasas. |
JP2007010876A (ja) | 2005-06-29 | 2007-01-18 | Fujinon Corp | レンズ駆動装置 |
CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
FR2889662B1 (fr) | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
WO2007038215A1 (en) | 2005-09-22 | 2007-04-05 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
NZ567133A (en) | 2005-09-30 | 2011-07-29 | Vertex Pharma | Deazapurines useful as inhibitors of janus kinases |
US20070128633A1 (en) | 2005-10-11 | 2007-06-07 | Chembridge Research Laboratories, Inc. | Cell-free protein expression systems and methods of use thereof |
PT1937664E (pt) | 2005-10-14 | 2011-07-07 | Sumitomo Chemical Co | Composto de hidrazida e utilização pesticida do mesmo |
BRPI0618011A2 (pt) | 2005-10-28 | 2011-08-16 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente |
NZ592990A (en) | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
WO2007062459A1 (en) | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
US20130137681A1 (en) | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
EP2348023B9 (en) | 2005-12-13 | 2017-03-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
EP1968568A4 (en) | 2005-12-22 | 2011-04-13 | Glaxosmithkline Llc | HEMMER OF NUTS ACTIVITY |
PL1962830T3 (pl) | 2005-12-23 | 2013-08-30 | Glaxosmithkline Llc | Azaindolowe inhibitory kinaz aurora |
TW201412738A (zh) | 2006-01-17 | 2014-04-01 | Vertex Pharma | 適合作為傑納斯激酶(janus kinase)抑制劑之氮雜吲哚 |
WO2007084667A2 (en) * | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
EP1981887A2 (en) | 2006-02-01 | 2008-10-22 | SmithKline Beecham Corporation | Pyrrolo[2,3,b]pyridine derivatives useful as raf kinase inhibitors |
US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
JPWO2007105637A1 (ja) | 2006-03-10 | 2009-07-30 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
CA2648303C (en) | 2006-04-03 | 2014-07-15 | Astellas Pharma Inc. | 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists |
CA2648250A1 (en) * | 2006-04-05 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
CA2647448A1 (en) | 2006-04-12 | 2007-10-18 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
US7691811B2 (en) | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
US20080021026A1 (en) | 2006-07-20 | 2008-01-24 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
JP5252404B2 (ja) | 2006-08-16 | 2013-07-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピラジン化合物、その使用及び調製方法 |
US20100029609A1 (en) | 2006-09-08 | 2010-02-04 | Frederic Berst | Biaryl sulfonamide derivatives |
WO2008035376A2 (en) | 2006-09-19 | 2008-03-27 | Council Of Scientific & Industrial Research | A novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof |
AR063141A1 (es) | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion |
CL2007002866A1 (es) | 2006-10-04 | 2008-07-04 | Pharmacopeia Inc | Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m |
US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
CN101600718B (zh) | 2006-11-06 | 2013-07-03 | 特雷罗药物股份有限公司 | 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途 |
US20080119496A1 (en) | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
SI3034075T1 (sl) | 2006-11-22 | 2018-12-31 | Incyte Holdings Corporation | Imidazotriazini in imidazopirimidini kot inhibitorji kinaze |
WO2008067119A2 (en) | 2006-11-27 | 2008-06-05 | Smithkline Beecham Corporation | Novel compounds |
NZ577111A (en) | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
CA2672903C (en) | 2006-12-20 | 2012-10-23 | Amgen Inc. | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer |
WO2008079291A2 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
CA2667072C (en) | 2006-12-22 | 2015-11-24 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
JP5492565B2 (ja) * | 2006-12-22 | 2014-05-14 | インサイト・コーポレイション | Janusキナーゼ阻害剤としての置換複素環 |
WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
WO2008082840A1 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
US8822497B2 (en) | 2007-03-01 | 2014-09-02 | Novartis Ag | PIM kinase inhibitors and methods of their use |
CN103214482B (zh) | 2007-04-03 | 2016-06-29 | 阵列生物制药公司 | 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物 |
GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
WO2008145681A2 (en) | 2007-05-31 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
CN101932582B (zh) | 2007-06-13 | 2013-09-25 | 因塞特公司 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
EP2175858B1 (en) | 2007-07-11 | 2014-09-10 | Pfizer Inc. | Pharmaceutical compositions and methods of treating dry eye disorders |
AU2008281543A1 (en) | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as Raf inhibitors |
WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
EP2217235A4 (en) | 2007-11-15 | 2011-01-12 | Musc Found For Res Dev | PROTEIN INHIBITORS PIM KINASES, COMPOSITIONS AND METHODS FOR TREATING CANCER |
EP2220068B1 (en) * | 2007-11-16 | 2016-01-27 | Incyte Holdings Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
GB0723815D0 (en) | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
PL3133080T3 (pl) | 2008-01-18 | 2018-12-31 | Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nowe cytostatyczne nukleozydy 7-deazapurynowe |
MX2010008376A (es) | 2008-02-04 | 2011-02-22 | Mercury Therapeutics Inc | Moduladores ampk. |
PE20091577A1 (es) | 2008-03-03 | 2009-11-05 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso |
UA101493C2 (ru) * | 2008-03-11 | 2013-04-10 | Инсайт Корпорейшн | Производные азетидина и циклобутана как ингибиторы jak |
EA201001456A1 (ru) | 2008-03-21 | 2011-06-30 | Новартис Аг | Новые гетероциклические соединения и их применение |
WO2009158687A1 (en) | 2008-06-26 | 2009-12-30 | Anterios, Inc. | Dermal delivery |
UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
FR2933409B1 (fr) | 2008-07-03 | 2010-08-27 | Centre Nat Rech Scient | NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM |
WO2010022081A1 (en) | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為pim激酶抑制劑之三唑吡啶化合物 |
ES2467109T3 (es) | 2008-08-20 | 2014-06-11 | Zoetis Llc | Compuestos de pirrolo[2,3-d]pirimidina |
WO2010026122A1 (en) | 2008-09-02 | 2010-03-11 | Novartis Ag | Heterocyclic pim-kinase inhibitors |
AU2009289316A1 (en) | 2008-09-02 | 2010-03-11 | Novartis Ag | Bicyclic kinase inhibitors |
EP2344474B1 (en) | 2008-09-02 | 2015-09-23 | Novartis AG | Picolinamide derivatives as kinase inhibitors |
CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
CN102458581B (zh) | 2009-05-22 | 2016-03-30 | 因塞特控股公司 | 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物 |
SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
US20120157500A1 (en) | 2009-08-24 | 2012-06-21 | Weikang Tao | Jak inhibition blocks rna interference associated toxicities |
TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
EP2475659B1 (en) | 2009-09-08 | 2015-10-28 | F.Hoffmann-La Roche Ag | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
KR20180126619A (ko) | 2009-10-09 | 2018-11-27 | 인사이트 홀딩스 코포레이션 | 3-(4-(7H-피롤로〔2,3-d〕피리미딘-4-일)-1H-피라졸-1-일)-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체 |
EP2491039A1 (en) | 2009-10-20 | 2012-08-29 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors |
EP2332917B1 (en) | 2009-11-11 | 2012-08-01 | Sygnis Bioscience GmbH & Co. KG | Compounds for PIM kinase inhibition and for treating malignancy |
WO2011066369A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to raise albumin and/or lower crp |
US20130129675A1 (en) | 2009-12-04 | 2013-05-23 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
RU2012132278A (ru) | 2010-01-12 | 2014-02-20 | Ф. Хоффманн-Ля Рош Аг | Трициклические гетероциклические соединения, содержащие их композиции и способы их применения |
SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
BR112012020693B1 (pt) | 2010-02-18 | 2020-05-12 | Incyte Holdings Corporation | Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende |
ME02386B (me) | 2010-03-10 | 2016-09-20 | Incyte Holdings Corp | Derivati piperidin-4-il azetidina kao inhibitori jak1 |
JP2013523884A (ja) | 2010-04-14 | 2013-06-17 | アレイ バイオファーマ、インコーポレイテッド | JAKキナーゼの阻害剤としての5,7置換イミダゾ[1,2−c]ピリミジン |
EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
KR102303885B1 (ko) | 2010-05-21 | 2021-09-24 | 인사이트 홀딩스 코포레이션 | Jak 저해제에 대한 국소 제형 |
US8637529B2 (en) | 2010-06-11 | 2014-01-28 | AbbYie Inc. | Pyrazolo[3,4-d]pyrimidine compounds |
US9351943B2 (en) | 2010-07-01 | 2016-05-31 | Matthew T. McLeay | Anti-fibroblastic fluorochemical emulsion therapies |
EP2621489A1 (en) | 2010-09-30 | 2013-08-07 | Portola Pharmaceuticals, Inc. | Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
CN101974161B (zh) | 2010-09-30 | 2012-10-31 | 中国科学院西双版纳热带植物园 | 一种溶解和快速水解木质纤维素生物质的方法及其设备和应用 |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
EP2640723A1 (en) | 2010-11-19 | 2013-09-25 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
CA2819560A1 (en) | 2010-12-03 | 2012-06-07 | Ym Biosciences Australia Pty Ltd | Treatment of jak2-mediated conditions |
CA2827673C (en) | 2011-02-18 | 2020-10-27 | Novartis Pharma Ag | Mtor/jak inhibitor combination therapy |
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
CA2844507A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | Jak pi3k/mtor combination therapy |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
EP2890691B1 (en) | 2012-08-31 | 2018-04-25 | Principia Biopharma Inc. | Benzimidazole derivatives as itk inhibitors |
US9263059B2 (en) | 2012-09-28 | 2016-02-16 | International Business Machines Corporation | Deep tagging background noises |
US20140095210A1 (en) | 2012-10-02 | 2014-04-03 | CareRev, Inc. | Computer-implemented method and system for facilitating information sharing, communication, and collaboration in a healthcare facility |
PE20151141A1 (es) | 2012-11-01 | 2015-08-06 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de jak |
EA201590930A1 (ru) | 2012-11-15 | 2015-08-31 | Инсайт Корпорейшн | Лекарственные формы руксолитиниба с замедленным высвобождением |
JP6397831B2 (ja) | 2013-03-06 | 2018-09-26 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤の製造方法及びその中間体 |
ME02763B (me) | 2013-05-17 | 2018-01-20 | Incyte Corp | Derivati bipirazola kao inhibitori jak |
TWI503855B (zh) | 2013-07-05 | 2015-10-11 | Timotion Technology Co Ltd | 極限開關及具有該開關之線性致動器 |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
JP2016528288A (ja) | 2013-08-20 | 2016-09-15 | インサイト・コーポレイションIncyte Corporation | 上昇したc反応性タンパク質レベルを有する固形腫瘍の患者における延命効果 |
SI3110409T1 (sl) | 2014-02-28 | 2018-11-30 | Incyte Corporation | Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov |
KR20230044320A (ko) | 2014-04-08 | 2023-04-03 | 인사이트 코포레이션 | Jak 및 pi3k 억제제 조합에 의한 b-세포 악성종양의 치료 |
SG10201809518QA (en) | 2014-04-30 | 2018-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
-
2008
- 2008-06-12 CN CN2008801029033A patent/CN101932582B/zh active Active
- 2008-06-12 CN CN201310367212.9A patent/CN103524509B/zh active Active
- 2008-06-12 PT PT87707949T patent/PT2173752E/pt unknown
- 2008-06-12 BR BRPI0814254A patent/BRPI0814254B8/pt active IP Right Grant
- 2008-06-12 KR KR1020157002074A patent/KR20150036210A/ko active Search and Examination
- 2008-06-12 EP EP16152794.0A patent/EP3070090B1/en not_active Revoked
- 2008-06-12 CU CU20120155A patent/CU24179B1/es active IP Right Grant
- 2008-06-12 ES ES18203965T patent/ES2903444T3/es active Active
- 2008-06-12 DK DK08770794.9T patent/DK2173752T4/da active
- 2008-06-12 US US12/137,892 patent/US20080312259A1/en not_active Abandoned
- 2008-06-12 PT PT16152794T patent/PT3070090T/pt unknown
- 2008-06-12 EA EA201070013A patent/EA019784B1/ru unknown
- 2008-06-12 RS RS20140152A patent/RS53245B2/sr unknown
- 2008-06-12 SG SG10201509887UA patent/SG10201509887UA/en unknown
- 2008-06-12 PL PL16152794T patent/PL3070090T3/pl unknown
- 2008-06-12 HU HUE16152794A patent/HUE043732T2/hu unknown
- 2008-06-12 DK DK13198120.1T patent/DK2740731T3/en active
- 2008-06-12 SG SG10201912675VA patent/SG10201912675VA/en unknown
- 2008-06-12 MY MYPI20095311A patent/MY154969A/en unknown
- 2008-06-12 NZ NZ581803A patent/NZ581803A/en unknown
- 2008-06-12 SI SI200832042T patent/SI3070090T1/sl unknown
- 2008-06-12 ES ES16152794T patent/ES2714092T3/es active Active
- 2008-06-12 WO PCT/US2008/066662 patent/WO2008157208A2/en active Application Filing
- 2008-06-12 CA CA2689663A patent/CA2689663C/en active Active
- 2008-06-12 SG SG2012043428A patent/SG182198A1/en unknown
- 2008-06-12 MX MX2013005828A patent/MX342814B/es unknown
- 2008-06-12 SI SI200831621A patent/SI2740731T1/sl unknown
- 2008-06-12 DK DK16152794.0T patent/DK3070090T3/en active
- 2008-06-12 KR KR1020107000805A patent/KR101549876B1/ko active IP Right Grant
- 2008-06-12 GE GEAP200811637A patent/GEP20125533B/en unknown
- 2008-06-12 PL PL08770794.9T patent/PL2173752T5/pl unknown
- 2008-06-12 EP EP13198120.1A patent/EP2740731B1/en active Active
- 2008-06-12 ES ES08770794T patent/ES2467665T5/es active Active
- 2008-06-12 EP EP08770794.9A patent/EP2173752B2/en active Active
- 2008-06-12 ES ES13198120.1T patent/ES2575797T3/es active Active
- 2008-06-12 SI SI200831217T patent/SI2173752T2/sl unknown
- 2008-06-12 AU AU2008266183A patent/AU2008266183B2/en active Active
- 2008-06-12 EP EP21200662.1A patent/EP4011883A1/en active Pending
- 2008-06-12 HU HUE13198120A patent/HUE029236T2/en unknown
- 2008-06-12 ME MEP-2009-345A patent/ME00960B/me unknown
- 2008-06-12 MX MX2009013402A patent/MX2009013402A/es active IP Right Grant
- 2008-06-12 LT LTEP16152794.0T patent/LT3070090T/lt unknown
- 2008-06-12 UA UAA201000232A patent/UA99467C2/ru unknown
- 2008-06-12 EP EP18203965.1A patent/EP3495369B1/en active Active
- 2008-06-12 RS RS20160375A patent/RS54878B1/sr unknown
- 2008-06-12 RS RS20190251A patent/RS58449B1/sr unknown
- 2008-06-12 PL PL13198120.1T patent/PL2740731T3/pl unknown
- 2008-06-12 JP JP2010512343A patent/JP5475653B2/ja active Active
- 2008-06-12 TR TR2019/03488T patent/TR201903488T4/tr unknown
-
2009
- 2009-12-06 IL IL202524A patent/IL202524A/en active IP Right Grant
- 2009-12-09 CR CR11151A patent/CR11151A/es unknown
- 2009-12-10 GT GT200900314A patent/GT200900314A/es unknown
- 2009-12-10 DO DO2009000280A patent/DOP2009000280A/es unknown
- 2009-12-10 ZA ZA2009/08826A patent/ZA200908826B/en unknown
- 2009-12-10 TN TNP2009000514A patent/TN2009000514A1/fr unknown
- 2009-12-11 NI NI200900216A patent/NI200900216A/es unknown
- 2009-12-11 CU CU2009000213A patent/CU23933B1/es active IP Right Grant
- 2009-12-14 EC EC2009009802A patent/ECSP099802A/es unknown
- 2009-12-16 CO CO09144142A patent/CO6251256A2/es active IP Right Grant
-
2010
- 2010-01-08 SM SM201000002T patent/SMP201000002B/it unknown
- 2010-01-12 MA MA32505A patent/MA31517B1/fr unknown
- 2010-10-14 HK HK10109728.8A patent/HK1143161A1/zh unknown
-
2013
- 2013-12-05 US US14/097,598 patent/US20140094477A1/en not_active Abandoned
- 2013-12-05 US US14/097,588 patent/US8722693B2/en active Active
-
2014
- 2014-04-18 US US14/256,311 patent/US8829013B1/en active Active
- 2014-04-18 US US14/256,383 patent/US8822481B1/en active Active
- 2014-05-01 IL IL232410A patent/IL232410A0/en active IP Right Grant
- 2014-05-06 US US14/270,915 patent/US9376439B2/en active Active
- 2014-05-07 CY CY20141100323T patent/CY1115145T1/el unknown
- 2014-06-09 HR HRP20140541TT patent/HRP20140541T4/hr unknown
- 2014-12-03 HK HK14112206.9A patent/HK1198652A1/zh unknown
-
2016
- 2016-05-25 US US15/164,518 patent/US10016429B2/en active Active
- 2016-06-13 CY CY20161100513T patent/CY1117693T1/el unknown
- 2016-06-21 HR HRP20160717TT patent/HRP20160717T1/hr unknown
-
2018
- 2018-06-08 US US16/003,210 patent/US10610530B2/en active Active
-
2019
- 2019-01-16 IL IL264276A patent/IL264276B/en active IP Right Grant
- 2019-02-28 HR HRP20190385TT patent/HRP20190385T1/hr unknown
- 2019-03-07 CY CY20191100273T patent/CY1121338T1/el unknown
- 2019-06-11 NO NO2019025C patent/NO2019025I1/no unknown
-
2020
- 2020-03-02 US US16/806,244 patent/US11213528B2/en active Active
-
2021
- 2021-01-26 IL IL280401A patent/IL280401B/en unknown
- 2021-10-31 IL IL287708A patent/IL287708B1/en unknown
- 2021-11-29 US US17/536,925 patent/US20220288078A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101932582B (zh) | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 | |
CN101815717B (zh) | JANUS激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的代谢产物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151204 Address after: American state of Patentee after: Because of C1-esteraseremmer-N parent corporation Address before: The United States Delaware Patentee before: Incyte Corp. |